A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

The partners’ ADC didn’t significantly extend survival in lung cancer patients who were expected to benefit the most from treatment in a Phase 3 trial.

Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the ...

AstraZeneca and Daiichi Sankyo have the confirmatory ... the number of cases of interstitial lung disease – a rare but serious side effect linked to Enhertu – was also in line with earlier ...

Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu ... complications with Enhertu, particularly interstitial lung disease (ILD).

Daiichi Sankyo's ADCs, particularly trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan ... with recent updates out of World Lung and other 2024 meetings letting us know that the pivotal ...

On the heels of receiving a landmark FDA approval in breast cancer, AstraZeneca and Daiichi Sankyo drug Enhertu won an additional approval in non-small cell lung cancer. The decision makes the ...

Merck MRK announced that a phase study evaluating its Daiichi ... Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell ...